Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: July 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205382

« Back to Dashboard

NDA 205382 describes INCRUSE ELLIPTA , which is a drug marketed by Glaxo Grp England and is included in one NDA. It is available from one supplier. There are ten patents protecting this drug. Additional details are available on the INCRUSE ELLIPTA profile page.

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the umeclidinium bromide profile page.

Summary for 205382

Tradename:	INCRUSE ELLIPTA
Applicant:	Glaxo Grp England
Ingredient:	umeclidinium bromide
Patents:	10

Generic Entry Opportunity Date for 205382

Generic Entry Date for 205382^: ➤ Sign Up* Constraining patent/regulatory exclusivity: ➤ Sign Up Dosage:: POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 205382

Mechanism of Action	Cholinergic Antagonists

Suppliers and Packaging for NDA: 205382

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
INCRUSE ELLIPTA	umeclidinium bromide	POWDER;INHALATION	205382	NDA	GlaxoSmithKline LLC	0173-0873	N	0173-0873-06
INCRUSE ELLIPTA	umeclidinium bromide	POWDER;INHALATION	205382	NDA	GlaxoSmithKline LLC	0173-0873	N	0173-0873-10

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;INHALATION			Strength	EQ 62.5MCG BASE/INH
Approval Date:	Apr 30, 2014	TE:		RLD:	Yes
Regulatory Exclusivity Expiration:	Dec 18, 2018
Regulatory Exclusivity Use:	NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:	Feb 24, 2019
Regulatory Exclusivity Use:	UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS
Patent:	➤ Sign Up	Patent Expiration:	Dec 18, 2027	Product Flag?	Y	Substance Flag?	Y	Delist Request?

Expired US Patents for NDA 205382

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxo Grp England	INCRUSE ELLIPTA	umeclidinium bromide	POWDER;INHALATION	205382-001	Apr 30, 2014	➤ Sign Up	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.